JPS6333314A - External preparation - Google Patents
External preparationInfo
- Publication number
- JPS6333314A JPS6333314A JP17820486A JP17820486A JPS6333314A JP S6333314 A JPS6333314 A JP S6333314A JP 17820486 A JP17820486 A JP 17820486A JP 17820486 A JP17820486 A JP 17820486A JP S6333314 A JPS6333314 A JP S6333314A
- Authority
- JP
- Japan
- Prior art keywords
- sorbic acid
- external preparation
- solution
- salt
- quasi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 20
- 239000004334 sorbic acid Substances 0.000 claims abstract description 20
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 10
- 239000006210 lotion Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 206010014970 Ephelides Diseases 0.000 abstract description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 4
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 4
- 208000010201 Exanthema Diseases 0.000 abstract description 3
- 102000003425 Tyrosinase Human genes 0.000 abstract description 3
- 108060008724 Tyrosinase Proteins 0.000 abstract description 3
- 201000005884 exanthem Diseases 0.000 abstract description 3
- 206010037844 rash Diseases 0.000 abstract description 3
- 231100000046 skin rash Toxicity 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- 238000010438 heat treatment Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 7
- -1 bags Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000010241 potassium sorbate Nutrition 0.000 description 7
- 239000004302 potassium sorbate Substances 0.000 description 7
- 229940069338 potassium sorbate Drugs 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000865 liniment Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940040145 liniment Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000004283 Sodium sorbate Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 2
- 235000019250 sodium sorbate Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野コ
本発明はソルビン酸またはその塩を有効成分として含有
してなる外用剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an external preparation containing sorbic acid or a salt thereof as an active ingredient.
本明細書にいう外用剤とは、化粧料のほかに外用に用い
られる医薬部外品（軟膏剤、ローション剤、リニメント
剤、乳剤など）を含む意味に用いられる。したがって、
本発明はさらに詳しくは、ソルビン酸またはその塩を有
効成分として含有してなる、色白効果のすぐれた化粧料
およびシミ、ソバカスなどの防止効果にすぐれた外用医
薬部外品に関するものである。As used herein, the term "external preparation" is used to include not only cosmetics but also quasi-drugs used for external use (ointments, lotions, liniments, emulsions, etc.). therefore,
More specifically, the present invention relates to a cosmetic composition containing sorbic acid or a salt thereof as an active ingredient, which has an excellent skin-whitening effect, and a quasi-drug for external use, which has an excellent effect of preventing spots, freckles, and the like.
［従来の技術および発明が解決しようとする問題点］
本発明の外用剤の有効成分である式：
％式％
であられされるソルビン酸またはその塩は、従来より食
品、化粧品の防腐剤として一般に用いられている。その
ばあい、化粧品での配合基準はソルビン酸として０．５
％以下とされている。[Prior art and problems to be solved by the invention] Sorbic acid or its salt, which is the active ingredient of the external preparation of the present invention and has the formula: % Formula %, has been generally used as a preservative for foods and cosmetics It is used. In that case, the standard for blending in cosmetics is 0.5 as sorbic acid.
% or less.
［問題点を解決するための手段］
しかるに本発明者は、ソルビン酸またはその塩が意外に
もチロシナーゼ抑制作用にもとづ（顕著なメラニン生成
抑制効果を有し、色白効果やシミ、ソバカスなどの防止
効果にすぐれていることを見出し、本発明を完成するに
いたった。[Means for Solving the Problems] However, the present inventor has discovered that sorbic acid or its salt surprisingly has a tyrosinase inhibitory effect (has a remarkable melanin production inhibiting effect, and has a fair skin effect, age spots, freckles, etc.). They discovered that it has an excellent preventive effect, leading to the completion of the present invention.
［作用および実施例］
本発明のソルビン酸の塩としては、ナトリウム塩および
カリウム塩などがあげられる。[Function and Examples] Examples of the salts of sorbic acid of the present invention include sodium salts and potassium salts.
本発明のソルビン酸のイン ビトロでのチロシナーゼ活
性抑制効果を調べた。試料液とじてソルビン酸（片山化
学■製）をエタノールに溶解し、５００ｍＭ 、３００
ａ＋Ｍ 、２００ｍＭおよび１１００Ｉｌ１のエタノー
ル溶液を調製した。酵素液（Ｂ１Ｂマウスメラノーマ細
胞３０００Ｇ上清） Ｏ，１ｍｌ、１０ｍＭｄｏｐａ
溶液１．０ｍｌ、 １００ｍＭリン酸バッファー（１）
Ｈ６，８） １．８７ ｍｌおよび試料液０．０３ｍ
１を３７℃でインキュベートし、３０秒ごとに４７５ｎ
ｍの吸光値を測定した。結果を第１表に示す。The in vitro inhibitory effect of sorbic acid on tyrosinase activity of the present invention was investigated. The sample solution was dissolved in ethanol (500mM, 300mM) and sorbic acid (manufactured by Katayama Chemical) was dissolved in ethanol.
An ethanol solution of a+M, 200mM and 1100Il1 was prepared. Enzyme solution (B1B mouse melanoma cell 3000G supernatant) O, 1ml, 10mM dopa
1.0ml of solution, 100mM phosphate buffer (1)
H6,8) 1.87 ml and sample solution 0.03 m
1 at 37°C, 475n every 30 seconds.
The absorbance value of m was measured. The results are shown in Table 1.
［以下余白］
本発明のソルビン酸またはその塩のメラニン生成抑制効
果を培養ＢｌＧマウスメラノーマ細胞を用いて調べた。[Margin below] The melanin production inhibiting effect of sorbic acid or its salt of the present invention was investigated using cultured BIG mouse melanoma cells.
ソルビン酸およびソルビン酸カリウム５Ｇ０．８５■を
それぞれエタノール１０ｍ１に溶解し、５００１Ｍ溶液
とした。本溶液を適宜１０％ウシ胎児血清を含むイーグ
ルＭＥＮ １０ｍ１に０．０２〜０．１ｍｌ添加した。Sorbic acid and potassium sorbate 5G0.85μ were each dissolved in 10 ml of ethanol to make a 5001M solution. 0.02 to 0.1 ml of this solution was added to 10 ml of Eagle MEN containing 10% fetal bovine serum as appropriate.
ソルビン酸またはソルビン酸カリウムの添加濃度を１．
ＯｍＭ、２．０ｇＭ、３．０ｍＭ、４．００１Ｍおよび
５．０ｍＭとしてメラニン生成抑制効果を調べたところ
、２．０ＩＭ以上の濃度で肉眼的に明らかにメラニン生
成の抑制を認めた。４．０ｍＭおよび５．ｈＭではほと
んどの細胞においてメラニン顆粒の消失が認められた。The concentration of sorbic acid or potassium sorbate added is 1.
When the melanin production inhibitory effect was investigated at OmM, 2.0 gM, 3.0 mM, 4.001 M and 5.0 mM, melanin production was clearly inhibited macroscopically at concentrations of 2.0 IM or higher. 4.0mM and 5. In hM, disappearance of melanin granules was observed in most cells.
本発明の外用剤は、ローション、バック、乳液、クリー
ムなどの一般の化粧料のかたちで用いられるほか、軟膏
剤、ローション剤、リニメント剤、乳剤などの外用の医
薬部外品のかたちでも用いられる。The external preparation of the present invention can be used in the form of general cosmetics such as lotions, bags, emulsions, and creams, as well as in the form of external quasi-drugs such as ointments, lotions, liniments, and emulsions. .
本発明の外用剤は、有効成分であるソルビン酸またはそ
の塩を化粧料のばあい０．０５〜５，０％、好ましくは
０．５〜３．０９６、医薬部外品のばあいは０．０５〜
１０．０％、好ましくは０．５〜５．０％含有する。The external preparation of the present invention contains 0.05 to 5.0% of the active ingredient sorbic acid or its salt in the case of cosmetics, preferably 0.5 to 3.096% in the case of quasi-drugs, and 0.0% in the case of quasi-drugs. .05～
It contains 10.0%, preferably 0.5 to 5.0%.
つぎに本発明を実施例および参考例を用いてさらに詳し
く説明するが、本発明はもとよりこれらに限られるもの
ではない。Next, the present invention will be explained in more detail using Examples and Reference Examples, but the present invention is not limited to these.
実施例１ （ローション）
１ ポリオキシエチレン硬化ヒマシ油（８０Ｅ、Ｏ，）
１．０ｇ
２ 香 料
微量３ エタノール １０．
０ ｇ４ パラオキシ安息香酸エステル ０．１ｇ５
グリチルリチン酸ジカリウム Ｏ，１ｇ６ ソルビ
ット液（７０％＞３．０ｇ
７ 濃グリセリン ３．０ｇ８ ソル
ビン酸カリウム １．０ｇ９ 精製水
全量１００ｇ１〜９を均一に撹拌溶解
してローション１００ｇを調製した。Example 1 (Lotion) 1 Polyoxyethylene hydrogenated castor oil (80E, O,)
1.0g 2 Flavoring
Trace amount 3 Ethanol 10.
0 g4 Paraoxybenzoic acid ester 0.1 g5
Dipotassium glycyrrhizinate O, 1g6 Sorbit solution (70%>3.0g 7 Concentrated glycerin 3.0g8 Potassium sorbate 1.0g9 Purified water
A total of 100 g of the ingredients 1 to 9 were uniformly stirred and dissolved to prepare 100 g of lotion.
実施例２（パック）
１ ポリビニルアルコール １２．０ｇ２ 酸
化チタン ４．０ｇ３ プロピレ
ングリコール ２．０ｇ４ ポリエチレング
リコール１５００ ２．０゜５ エタノール
１０．０Ｆ：６ ソルビン酸
２．０ｇ７ 精製水
全ｆｆｉ １００ｇ１〜７を均一に撹拌混合してバック
１００ｇを調製した。Example 2 (pack) 1 Polyvinyl alcohol 12.0g2 Titanium oxide 4.0g3 Propylene glycol 2.0g4 Polyethylene glycol 1500 2.0°5 Ethanol
10.0F:6 Sorbic acid
2.0g7 Purified water
100 g of total ffi 1 to 7 were uniformly stirred and mixed to prepare 100 g of bag.
実施例３（乳液）
１ モノステアリン酸ポリオキシ
エチレンソルビタン（２０Ｅ、０．） １．０ｇ２
テトラオレイン酸ポリオキシ
エチレンソルビット（６０Ｅ、Ｏ，） ０．５ｇ３
親油型モノステアリン酸グリセリン１．０ｇ
４ ステアリン酸 ０．５゜５ ベ
ヘニルアルコール ｏ、ｓｇ６ アボカド
油 ４．０１７ トリオクタン酸
グリセリル ４．０ｇ８ 天然ビタミンＥ
０．０２ｇ９ ハラオキシ安息香酸エス
テル ０．２ｇ１０ キサンタンガム
０．１４ｇ１１ １．３−ブチレングリコール
５．０ｇ１２ エタノール
２．０ｇ１３ ソルビン酸ナトリウム
１．５ｇ１４ 香料
微量１５ 精製水 全量１０
０ｇ１〜９を加温溶解しくＡ液）、これとは別に１０．
１１および１５を加温溶解した（Ｂ液）。Ａ液にＢ液を
加え乳化撹拌し、冷却した（Ｃ液）。Example 3 (emulsion) 1 Polyoxyethylene sorbitan monostearate (20E, 0.) 1.0g2
Polyoxyethylene sorbitol tetraoleate (60E, O,) 0.5g3
Lipophilic glyceryl monostearate 1.0g 4 Stearic acid 0.5゜5 Behenyl alcohol o, sg6 Avocado oil 4.017 Glyceryl trioctanoate 4.0g8 Natural vitamin E
0.02g9 Haloxybenzoic acid ester 0.2g10 Xanthan gum
0.14g11 1.3-butylene glycol
5.0g12 ethanol
2.0g13 Sodium sorbate
1.5g14 fragrance
Trace amount 15 Purified water Total amount 10
Dissolve 0g1-9 by heating (liquid A), and separately 10.
11 and 15 were dissolved by heating (solution B). Solution B was added to solution A, stirred to emulsify, and cooled (solution C).
Ｃ液に１２〜１４を加え、撹拌混合し、冷却して乳液１
００ｇを調製した。Add 12 to 14 to liquid C, stir and mix, cool and make emulsion 1.
00g was prepared.
実施例４（クリーム）
１ モノステアリン酸ポリオキシ
エチレンソルビタン（２０Ｂ、０．） １．０ｇ−
２テトラオレイン酸ポリオキシ
エチレンソルビット（６０Ｂ、０．） １．５ｇ３
親油型モノステアリン酸グリセリン１．５ｓｒ
４ サラシミッロウ ２．０ｇ５ パラ
フィン ２．０ｇ６ ステアリン酸
３．０ｇ７ ベヘニルアルコール
ｌＬＯｇ８ 流動パラフィン
５．０ｇ９ アルモンド油
１２．０ｇ１Ｏ天然ビタミンＥ ０６
０２ｇ１１ メチルポリシロキサン ０．
１ｇ１２ ハラオキシ安息香酸エステル ０．２ｇ
ｌ５ １，３−ブチレングリコール ５．０゜
１４ エタノール ２．０゜１
５ ソルビン酸カリウム ３．０ｇｌ６
香料 微量１７ 精
製水 全１１ ｔｏｏ１ｒ１〜１２
を加温溶解しくＡ液）、これとは別に１３および１７を
加温溶解した（Ｂ液）。Ａ液にＢ液を加え乳化撹拌し、
冷却した（Ｃ液）。Ｃ液に１４〜１Ｂを加え、撹拌混合
し、冷却してクリーム１００ ｇを調製した。Example 4 (cream) 1 Polyoxyethylene sorbitan monostearate (20B, 0.) 1.0 g-
2-tetraoleate polyoxyethylene sorbitol (60B, 0.) 1.5g3
Lipophilic glycerin monostearate 1.5sr 4 Sarashimilow 2.0g5 Paraffin 2.0g6 Stearic acid 3.0g7 Behenyl alcohol lLOg8 Liquid paraffin
5.0g9 Almond oil
12.0g1O natural vitamin E 06
02g11 Methylpolysiloxane 0.
1g12 Haloxybenzoic acid ester 0.2g
l5 1,3-butylene glycol 5.0゜14 Ethanol 2.0゜1
5 Potassium sorbate 3.0gl6
Fragrance trace amount 17 Purified water total 11 too1r1~12
was dissolved by heating (solution A), and separately 13 and 17 were dissolved by heating (solution B). Add liquid B to liquid A and stir to emulsify.
It was cooled (liquid C). 14-1B was added to Solution C, stirred and mixed, and cooled to prepare 100 g of cream.
実施例５（軟膏剤）
１ モノステアリン酸ポリオキシ
エチレンソルビタン（２０Ｅ、Ｏ，） ｉ、ｏｇ２
テトラオレイン酸ポリオキシ
エチレンソルビット（４０Ｅ、Ｏ，） １．５ｇ３
自己乳化型モノステアリン酸グリセリン１．５ｇ
４ サラシミッロウ ２．０ｇ５ パ
ラフィン ３．０ｇ６ ステアリン
酸 ３．０ｇ７ ベヘニルアルコー
ル ３．０ｇ８ 流動パラフィン
５．０ｇ９ トリオクタン酸グリセリル
２０．０ｇ１Ｏハラオキシ安息香酸エステル ０．
２ｇ１１ グリセリン ５．０ｇ
１２ 水酸化ナトリウム ０．０２Ｅ：
１３ エタノール ２．０ｇ１
４ ソルビン酸 ５．０ｇ１５
精製水 全量１００ｇ１〜１０を
加温溶解しくＡｉｔ＆）、これとは別に１１、Ｉ２およ
び１５を加温溶解した（Ｂ液）。Ａ液にＢ液を加え乳化
撹拌し、冷却した（Ｃ液）。Example 5 (Ointment) 1 Polyoxyethylene sorbitan monostearate (20E, O,) i, og2
Polyoxyethylene sorbitol tetraoleate (40E, O,) 1.5g3
Self-emulsifying glycerin monostearate 1.5g 4 Sarashimiro 2.0g5 Paraffin 3.0g6 Stearic acid 3.0g7 Behenyl alcohol 3.0g8 Liquid paraffin
5.0g9 Glyceryl trioctanoate
20.0g1O halaoxybenzoic acid ester 0.
2g11 Glycerin 5.0g
12 Sodium hydroxide 0.02E:
13 Ethanol 2.0g1
4 Sorbic acid 5.0g15
A total of 100 g of purified water 1 to 10 was dissolved by heating (Ait&), and separately 11, I2, and 15 were dissolved by heating (solution B). Solution B was added to solution A, stirred to emulsify, and cooled (solution C).
Ｃ液に１３および１４を加え、撹拌混合し、冷却して軟
膏剤ｔｏｏｒを調製した。13 and 14 were added to Solution C, stirred and mixed, and cooled to prepare ointment toor.
実施例６（ローション剤）
１ ポリオキシエチレン硬化ヒマシ油（ｔｉＯＥ、ｏ、
）１．０ｇ
２ エタノール １５．０ｇ３
パラオキシ安息香酸エステル ０．１ｇ４ クエン酸
０．１ｇ５ クエン酸ナトリ
ウム ０．３ｇ６１．３−ブチレングリコ
ール ４．０ｇ７ ソルビン酸ナトリウム
２．０ｇ８ 精製水 全量
１００ｇ１〜８を均一に撹拌溶解してローション剤１０
０ｇを調製した。Example 6 (Lotion) 1 Polyoxyethylene hydrogenated castor oil (tiOE, o,
)1.0g 2 Ethanol 15.0g3
Paraoxybenzoic acid ester 0.1g4 Citric acid 0.1g5 Sodium citrate 0.3g6 1.3-Butylene glycol 4.0g7 Sodium sorbate
2.0g8 Purified water Total amount 100g Stir and dissolve 1 to 8 uniformly to make lotion 10
0g was prepared.
実施例７（リニメント剤）
１ トラガント ５．０ｇ２ グ
リセリン １０．０ｇ３ エタノール
ｉｏ、０ｇ４ ソルビン酸カリ
ウム １．０ｇ５ 精製水
全量１００ ｇ１〜５を均一に撹拌混合してリニ
メント剤１００ ｇを調製した。Example 7 (Liniment agent) 1 Tragacanth 5.0g2 Glycerin 10.0g3 Ethanol io, 0g4 Potassium sorbate 1.0g5 Purified water
A total of 100 g of liniment agents 1 to 5 were uniformly stirred and mixed to prepare 100 g of liniment agent.
実施例８（乳剤）
１ モノステアリン酸ポリオキシ
エチレンソルビタン（２０Ｅ、０．） １．０ｇ２
テトラオレイン酸ポリオキシ
エチレンソルビット（４０Ｅ、０．） ０．５ｇ３
親油型モノステアリン酸グリセリン１．０ｇ
４ ステアリン酸 ０．５ｇ−５ベ
ヘニルアルコール ０．５ｇ６ 流動パラフ
ィン ４．０ｇ７ トリオクタン酸グリ
セリル ４．０ｇ８ オクタン酸セチル
２．０ｇ９ パラオキシ安息香酸エステル ０
．２ｇ１０ カルボキシビニルポリマー ０．０
５ｇ１１ １．８−ブチレングリコール ５．
０ｇ１２ 水酸化ナトリウム ０．０２
５ｇ１３ エタノール ２．０
ｇ１４ ソルビン酸カリウム ３．０ｇ
１５ 精製水 全量１００ ｇ１
〜９を加温溶解しくＡ液）、これとは別にｔｏ−１２お
よび１５を加温溶解した（Ｂ液）。Ａ液にＢ液を加え乳
化撹拌し、冷却した（Ｃ液）。Example 8 (emulsion) 1 Polyoxyethylene sorbitan monostearate (20E, 0.) 1.0g2
Polyoxyethylene sorbitol tetraoleate (40E, 0.) 0.5g3
Lipophilic glyceryl monostearate 1.0g 4 Stearic acid 0.5g-5Behenyl alcohol 0.5g6 Liquid paraffin 4.0g7 Glyceryl trioctanoate 4.0g8 Cetyl octoate
2.0g9 Paraoxybenzoic acid ester 0
．． 2g10 carboxyvinyl polymer 0.0
5g11 1.8-Butylene glycol 5.
0g12 Sodium hydroxide 0.02
5g13 ethanol 2.0
g14 Potassium sorbate 3.0g
15 Purified water total amount 100 g1
-9 was dissolved by heating (liquid A), and separately to-12 and 15 were dissolved by heating (liquid B). Solution B was added to solution A, stirred to emulsify, and cooled (solution C).
Ｃ液に１３および１４を加え、撹拌混合し、冷却して乳
剤ｌｏｎｇを調製した。13 and 14 were added to Solution C, stirred and mixed, and cooled to prepare emulsion long.
実施例９
実施例１〜４でえられた化粧料それぞれについて、任意
に選んだ６０人の男女（男３０人、女３０人、年齢２０
〜５０歳のあいだでほぼ均一に抽出）に３力月間使用し
てもらい、安全性および効能についてのアンケートをと
った。結果を第２表に示す。Example 9 For each of the cosmetics obtained in Examples 1 to 4, 60 randomly selected men and women (30 men, 30 women, age 20
Participants (approximately uniformly distributed between the ages of 50 to 50) used the product for 3 months and completed a questionnaire regarding safety and efficacy. The results are shown in Table 2.
［以下余白］
実施例１０
実施例５〜８でえられた外用医薬部外品それぞれについ
て、任意に選んだ６０人の男女（男３０、人、女３０人
、年齢２０〜５０歳のあいだでほぼ均一に抽出）に３力
月間使用してもらい、安全性および効能についてのアン
ケートをとった。結果を第３表に示す。[Left below] Example 10 For each of the external quasi-drugs obtained in Examples 5 to 8, 60 randomly selected men and women (30 men, 30 women, between the ages of 20 and 50) were tested. (Extracted almost uniformly) used the product for three months, and completed a questionnaire regarding safety and efficacy. The results are shown in Table 3.
［以下余白］
第２表および第３表の結果から、本発明の外用剤は肌ア
レ、皮膚のカブレなどを生じることがほとんどなく安全
に使用することができ、また色白結果、シミ、ソバカス
防止効果においてもすぐれていることがわかる。[Margins below] From the results in Tables 2 and 3, it is clear that the external preparation of the present invention hardly causes any skin irritation or rash, and can be used safely. It can be seen that the effect is also excellent.
参考例
本発明のソルビン酸の貼布試験を、２０歳から５９歳に
わたる健康成人５０名（男２０名、女３０名）を対象と
し、つぎの条件で試みた。Reference Example A patch test of the sorbic acid of the present invention was conducted on 50 healthy adults (20 men, 30 women) aged 20 to 59 under the following conditions.
試験薬剤：
ソルビン酸カリウム５．０％水溶液
コントロール（生理食塩水）
貼布時間：４８時間
貼布部位：上腕内側皮膚
貼布剤：パッチテスト用絆創膏
（大正製薬株式会社製）
貼布４８時間後の判定の結果、ソルビン酸はコントロー
ルと同様、陽性反応を示したものは全くなかった。Test drug: Potassium sorbate 5.0% aqueous solution control (physiological saline) Application time: 48 hours Application site: Inner upper arm skin Patch: Patch test adhesive plaster (manufactured by Taisho Pharmaceutical Co., Ltd.) 48 hours after application As a result of the determination, sorbic acid showed no positive reaction at all, similar to the control.
［発明の効果］
本発明の外用剤は肌アレ、皮膚のカブレなどを生じるこ
となく安全に使用することができ、色白効果、シミ、ソ
バカス防止効果がすぐれているという効果を奏する。[Effects of the Invention] The external preparation of the present invention can be safely used without causing skin irritation or skin rash, and has excellent effects of whitening the skin and preventing spots and freckles.
Claims (1)
なる外用剤。1. An external preparation containing sorbic acid or its salt as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17820486A JPS6333314A (en) | 1986-07-29 | 1986-07-29 | External preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17820486A JPS6333314A (en) | 1986-07-29 | 1986-07-29 | External preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6333314A true JPS6333314A (en) | 1988-02-13 |
Family
ID=16044394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17820486A Pending JPS6333314A (en) | 1986-07-29 | 1986-07-29 | External preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6333314A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02147235A (en) * | 1988-11-29 | 1990-06-06 | Toshiba Chem Corp | Circuitry substrate and manufacture thereof |
| JPH02308593A (en) * | 1989-05-23 | 1990-12-21 | Mitsubishi Electric Corp | Epoxy resin copper coated laminated board |
| WO1996038135A1 (en) * | 1995-05-31 | 1996-12-05 | Schering Ag | Sorbic-acid-containing hydrogels |
| JP2016510775A (en) * | 2013-03-11 | 2016-04-11 | バイエルスドルフ・アクチエンゲゼルシヤフトＢｅｉｅｒｓｄｏｒｆ ＡＧ | Combinations comprising alkylamidothiazoles and preservatives |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6281304A (en) * | 1985-10-01 | 1987-04-14 | Lion Corp | Emulsified cosmetic compounded with crude drug |
-
1986
- 1986-07-29 JP JP17820486A patent/JPS6333314A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6281304A (en) * | 1985-10-01 | 1987-04-14 | Lion Corp | Emulsified cosmetic compounded with crude drug |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02147235A (en) * | 1988-11-29 | 1990-06-06 | Toshiba Chem Corp | Circuitry substrate and manufacture thereof |
| JPH02308593A (en) * | 1989-05-23 | 1990-12-21 | Mitsubishi Electric Corp | Epoxy resin copper coated laminated board |
| WO1996038135A1 (en) * | 1995-05-31 | 1996-12-05 | Schering Ag | Sorbic-acid-containing hydrogels |
| JP2016510775A (en) * | 2013-03-11 | 2016-04-11 | バイエルスドルフ・アクチエンゲゼルシヤフトＢｅｉｅｒｓｄｏｒｆ ＡＧ | Combinations comprising alkylamidothiazoles and preservatives |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61155302A (en) | Skin color-lightening cosmetic | |
| BR102012017032A2 (en) | Methods and compositions containing zinc oxide for treating and / or preventing enzymatic irritation | |
| JP3665360B2 (en) | Active oxygen scavenger and composition containing the same | |
| JPS638314A (en) | Drug for external use | |
| AU633578B2 (en) | Melanogenesis-inhibiting preparation for external application | |
| JPS638315A (en) | Drug for external use | |
| JPS6333314A (en) | External preparation | |
| JPH09291012A (en) | Antiphlogistic skin cosmetic | |
| JPS6330403A (en) | Agent for external use | |
| JP2018150266A (en) | Skin external preparation for preventing and/or improving pimples | |
| JPS6323809A (en) | Drug for external use | |
| JPS6322509A (en) | External preparation | |
| JPS638316A (en) | Drug for external use | |
| JPH1129467A (en) | Protease inhibitor | |
| JPS6333313A (en) | External preparation | |
| JPH01275516A (en) | Dandruff-preventive agent and hair-cosmetic | |
| JP6822648B2 (en) | Tryptase inhibitor composition | |
| JPS63183518A (en) | Composition for hair | |
| JPS6322508A (en) | External preparation | |
| JPH0210125B2 (en) | ||
| JPS6366802B2 (en) | ||
| JPH01228908A (en) | External medicine for inhibiting production of melamine | |
| BR102012017030A2 (en) | Methods and compositions containing divalent cations / talc for treatment and / or prevention of enzymatic irritation | |
| JPS60188306A (en) | Cosmetic | |
| JPH07242542A (en) | Cosmetic |